Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

Boston Scientific Corp (BSX) reports impressive Q4 2024 results with 22.4% revenue growth and a 26% increase in adjusted EPS, ...

Most people aren’t aware of the symptoms, especially if they’re otherwise healthy, because they don’t know that AFib can affect anyone!

Securities adjusted its outlook on Boston Scientific (NYSE:BSX) shares, raising the price target to $130 from $110 while ...

Truist Securities expressed a positive outlook on Boston Scientific (NYSE:BSX) shares, raising the price target to $120 from $110, while reaffirming a Buy rating. The stock, currently trading near its ...